Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.59 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.53 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP3A5 | P20815 | 3/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.37 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3873020 | 0.86 | CYP19A1 (0.59) | CYP19A1CYP11B1SLC6A4KEAP1SLC9A1 | |
| SCHEMBL10674497 | 0.77 | CYP19A1 (1.00) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3873316 | 0.75 | CNR1 (0.49) | CYP19A1CYP11B1KEAP1 | |
| SCHEMBL8884360 | 0.75 | CYP19A1 (0.60) | CYP19A1CYP11B1SLC6A4KEAP1NFE2L2 | |
| SCHEMBL9026711 | 0.74 | CYP19A1 (0.58) | CYP19A1CYP11B1SLC6A4KEAP1SLC9A1 | |
| Bromide SCHEMBL8884686 | 0.73 | CYP19A1 (0.57) | CYP19A1CYP11B1SLC6A4KEAP1NFE2L2 | |
| SCHEMBL9681284 | 0.73 | CYP19A1 (0.49) | CYP19A1CYP11B1SLC6A4KEAP1NFE2L2 | |
| SCHEMBL9523659 | 0.72 | CYP19A1 (0.50) | CYP19A1CYP11B1SLC6A4KEAP1CYP3A4 | |
| SCHEMBL9523312 | 0.71 | CYP19A1 (0.65) | CYP19A1CYP11B1CYP3A4 | |
| SCHEMBL8714052 | 0.71 | CYP19A1 (0.55) | CYP19A1CYP11B1SLC6A2SLC6A4KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874304-B1 | BENZOTRIAZOLE DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-15 | — | — | EP | claimed |
| US-20080194656-A1 | Benzotriazole Derivatives as Cannabinoid Receptor Antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | claimed |
| EP-1874304-A2 | BENZOTRIAZOLE DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-09 | — | — | EP | claimed |
| WO-2006117307-A2 | BENZOTRIAZOLE DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-09 | — | — | WO | claimed |
| EP-1874304-B1 | BENZOTRIAZOLE DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-15 | — | — | EP | disclosed |
| US-20080194656-A1 | Benzotriazole Derivatives as Cannabinoid Receptor Antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
| EP-1874304-A2 | BENZOTRIAZOLE DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006117307-A2 | BENZOTRIAZOLE DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194656-A1 | Benzotriazole Derivatives as Cannabinoid Receptor Antagonists | CNR1, CNR2, HTR3C | CYP19A1 1108/4885CYP11B1 362/4885CFTR 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.